key: cord-1029103-184h47gx
authors: Tammaro, Antonella; Adebanjo, Ganiyat Adenike Ralitsa; Magri, Francesca; Parisella, Francesca Romana; Chello, Camilla; De Marco, Gabriella
title: Local skin reaction to the AZD1222 vaccine in a patient who survived COVID‐19
date: 2021-05-22
journal: J Cosmet Dermatol
DOI: 10.1111/jocd.14205
sha: bd5744ea3ea88c00388a806b8875f8afadd7d979
doc_id: 1029103
cord_uid: 184h47gx

Since the beginning of the COVID-19 pandemic strenuous efforts to create a herd immunity against this deadly disease have been made. As a matter of fact, multiple vaccines harnessing different strategies have been developed: virus-like vaccines, protein subunit vaccines, RNA-based vaccines, inactivated vaccines, protein subunit vaccines and vector vaccines have been created by the international scientific community.

To the Editor, Since the beginning of the COVID-19 pandemic, strenuous efforts to create a herd immunity against this deadly disease have been made. As a matter of fact, multiple vaccines harnessing different strategies have been developed: virus-like vaccines, protein subunit vaccines, RNA-based vaccines, inactivated vaccines, protein subunit vaccines, and vector vaccines have been created by the international scientific community. 1 The vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have been approved in Italy are the mRNA vaccines and the viral vector vaccines Ad26.COV2.S and AZD1222. 2 We report the cutaneous reaction after the AZD122 vaccine of a patient with no history of allergy.

A 35-year-old woman was presented because of cutaneous lesions which had appeared after the administration of the AZD122 vaccine.

She reported that the day after the vaccine administration, she experienced fever, nausea, and pain on the site of injection for two consecutive days. Additionally, six days after the vaccination she noticed the appearance of a cutaneous rash on her calves in association to pruritus and warmth. After a consultation with her general practitioner, she took ebastine 10 mg and 2 tablets of betamethasone 1 mg.

Unfortunately, two days later she developed vesicular lesions on top of that rash ( Figure 1 ). Hence, she took ebastine and betamethasone: One hour later, the vesicular lesions were substituted by white discolorations.

On physical examination, we detected an extended erythematous rash on the legs of the patient associated to hypopigmented areas.

We decided to treat the patient by continuing the administration of ebastine and tapered betamethasone for four days. The lesions disappeared completely afterward. Importantly, the patient had been hospitalized because of severe COVID-19 a few months before.

We believe that the local cutaneous reaction experienced by this patient may presumptively be considered the result a nonspecific inflammatory reaction linked to the administration of the vaccine because of the temporal correlation.

Real allergic reactions to vaccines are rare events, and they may be linked to a direct response or cross-reaction to preservatives and excipients. 3 The AZD1222 vaccine developed by AstraZeneca/Oxford University contains the wild-type SARS-CoV-2 spike protein which is vectored by the attenuated adenovirus ChAdOx1 (a simian virus). 1 Notably, this vaccine against the novel coronavirus has been administered to the population since January 2021. 1 The potential excipient of this vaccine that may trigger allergic reactions is polysorbate 80. 

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. Npj Vaccines

COVID-19 Vaccines | Italian Medicines Agency. Accessed

Vaccine allergy

Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience